Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of more-effective, safer, and/or better-tolerated therapies, such as the sodium glucose contransporter-2 (SLGT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have provided physicians with a broad array of therapeutic options. Moreover, with better understanding of type 2 diabetes and its complications, individualization of treatment is becoming more common. Numerous branded agents from both established and recently emergent classes are now jostling for position in the treatment paradigm.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The Treatment Algorithms dashboard supplements our claims data analysis report and retains the full set of analyses included in the PowerPoint-based report. The interactive dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.